NUVB — Nuvation Bio Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1811063 ·
Last close
$4.92
Market Cap
$1.71B
52W High
$5.64
52W Low
$4.05
ADV30
4,740,547
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 83,228,000 | 77,237,000 | 3,881,000 | 5,397,000 | 610,241,000 | 125,391,000 | 290,677,000 |
| Dec 2025 | 41,865,000 | 40,586,000 | -34,037,000 | -36,592,000 | 594,822,000 | 164,086,000 | 289,106,000 |
| Sep 2025 | 13,120,000 | 9,771,000 | -56,434,000 | -55,792,000 | 601,561,000 | 98,897,000 | 275,679,000 |
| Jun 2025 | 4,833,000 | 2,257,000 | -63,589,000 | -59,007,000 | 647,225,000 | 247,970,000 | 274,318,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-125,731,000
Investing CF
$1,702,000
Financing CF
$202,031,000
CapEx
$-8,330,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,109,973,000
Inventory
$15,844,000
Receivables
$25,984,000
ST Investments
$408,338,000
EBIT TTM
$-125,658,000
Pretax Income TTM
$-145,994,000
Interest Exp TTM
$20,336,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$143,046,000
EBITDA
$-148,214,000
Free Cash Flow
$-100,037,872
Enterprise Value
$1,396,408,704
Total Cash
$533,728,992
Total Debt
$216,984,000
Shares Out
347,201,971
Trailing EPS
$-0.43
Book Value
$0.92
ROE
-39.5%
ROA
-17.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 62,902,000 | -213,064,000 | -204,627,000 | 594,822,000 | 289,106,000 | — | -173,427,000 |
| Dec 2024 | 7,873,000 | -167,557,000 | -567,939,000 | 540,626,000 | 76,838,000 | — | -130,413,000 |
| Dec 2023 | 0 | -99,822,000 | -75,802,000 | 621,484,000 | 16,362,000 | — | -67,999,000 |
| Dec 2022 | 0 | -119,734,000 | -104,199,000 | 672,141,000 | 17,065,000 | — | -96,108,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHVN | Biohaven Ltd. | $1.70B | $11.28 | — |
| MBX | MBX Biosciences, Inc. | $1.69B | $35.51 | — |
| INVA | Innoviva, Inc. | $1.68B | $22.74 | — |
| QURE | uniQure N.V. | $1.74B | $27.57 | — |
| ZYME | Zymeworks Inc. | $1.67B | $22.88 | — |
News headlines (Yahoo Finance, 1h cache)
Spotlight On Promising Penny Stocks For June 2026
2026-06-10 12:05 · Yahoo
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
2026-05-27 20:05 · Yahoo
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
2026-05-27 12:00 · Yahoo
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps
2026-05-18 11:07 · Yahoo
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
2026-05-18 04:29 · Yahoo
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
2026-05-15 23:02 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
2026-05-15 22:50 · Yahoo
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
2026-05-15 21:59 · Yahoo
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
2026-05-13 20:05 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-06-11 20:02:51 | 2026-06-09 | Mashal Robert | Dir | P - Purchase | 4.73 | 25000 | 118250 |